- Home
- IMSR vs ACIU Comparison
IMSR vs ACIU Comparison
Compare IMSR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMSR | ACIU |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 213.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | IMSR | ACIU |
|---|---|---|
| Price | $8.32 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $738.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1234.25 | N/A |
| 52 Week Low | $7.52 | $1.43 |
| 52 Week High | $31.50 | $4.00 |
Technical Indicators
Market Signals| Indicator | IMSR | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.27 |
| Support Level | N/A | $2.54 |
| Resistance Level | N/A | $3.80 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 52.38 |
Price Performance
Historical ComparisonAbout IMSR Terrestrial Energy Inc.
Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.